Advertisement

DTIC: A Springboard to New Antitumour Agents

  • M. F. G. Stevens
Chapter
Part of the Developments in Pharmacology book series (DIPH, volume 3)

Abstract

Although the history of the development of 5- (3, 3-dimethyl-triazen-l-yl) imidazole-4-carboxamide (DTIC; NSC 45388) has been fully documented (1–5) a definitive account of the mode of action of the drug has yet to appear. There are almost as many theories purporting to explain the mode of action of DTIC as there are chemists and biochemists who, ensnared by the apparent deceptive simplicity of the molecule, have responded to the challenge but abjectly failed in the task of unravelling its perverse secrets.

Keywords

Anti Tumour Cancer Treatment Report Antitumour Agent Aryldiazonium Salt Lewis Lung Tumour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schepartz SA. (1976) Cancer Treatment Reports, 60, 123–124.PubMedGoogle Scholar
  2. 2.
    Montgomery JA. (1976) Cancer Treatment Reports,60, 125–134.PubMedGoogle Scholar
  3. 3.
    Venditti JM. (1976) Cancer Treatment Reports, 60, 135–140.PubMedGoogle Scholar
  4. 4.
    Bono VH. (1976) Cancer Treatment Reports, 60, 141–148.PubMedGoogle Scholar
  5. 5.
    Shealy YF. (1970) J. Pharm. Sci., 59, 1533–1558.PubMedCrossRefGoogle Scholar
  6. 6.
    Stevens MFG (1976) Progr. Medicin. Chem., 13, 205–269.CrossRefGoogle Scholar
  7. 7.
    Vaughan K, Stevens MFG. (1978) Chem. Soc. Rev., 7, 377–397.CrossRefGoogle Scholar
  8. 8.
    Kreis W. (1977) Cancer, a Comprehensive Treatise. Ed. Becker FF. Plenum Press, Vol. 5, pp. 489–519.Google Scholar
  9. 9.
    Julliard M, Vernin G. (1981) Bull. Soc. chim. France II, 150–159.Google Scholar
  10. 10.
    Shealy YF, Krauth CA, Montgomery JA. (1962) J. Org. Chem.,27. 2150–2154.CrossRefGoogle Scholar
  11. 11.
    Shealy YF, Struck RF, Holum LB, Montgomery JA. (1961) J. Org. Chem., 26, 2396–2401.CrossRefGoogle Scholar
  12. 12.
    Horton JK, Stevens MFG. (1981) J.C.S. Perkin Trans. I, 1433–1436.CrossRefGoogle Scholar
  13. 13.
    Saunders PP, Schultz GA. (1970) Biochem.Pharmacol., 19, 911–919.PubMedCrossRefGoogle Scholar
  14. 14.
    Gerulath AH, Ti Li Loo, (1972) Biochem. Pharmacol., 21, 2335–2343.PubMedCrossRefGoogle Scholar
  15. 15.
    Gerulath AH, Barranco SC, Humphrey RM. (1974) Cancer Res., 34, 1921–1925.PubMedGoogle Scholar
  16. 16.
    Saunders PP, Chao L-Y. (1974) Cancer Res., 34, 2464–2469.PubMedGoogle Scholar
  17. 17.
    Baird GM, Willoughby MLN. (1978) Lancet, 681.Google Scholar
  18. 18.
    Shealy YF, Krauth CA, Clayton SJ, Shortnacy AT, Laster WR. (1968) J. Pharm. Sci., 57, 1562–1568.PubMedCrossRefGoogle Scholar
  19. 19.
    Horton JK, Stevens MFG. (1981) J. Pharm. Pharmacol., 33, 808–811.PubMedCrossRefGoogle Scholar
  20. 20.
    Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K, Asano K, Matsuda T. (1974) J. Antibiotics, 27, 775–782.Google Scholar
  21. 21.
    Mizuno K, Yaginuma S, Hayashi M, Takada M, Muto N, (1975) J. Ferment. Technol., 53, 609–619.Google Scholar
  22. 22.
    Ambroz HB, Golding BT, Kemp TJ. (1982) J.C.S. Chem. Commun., 414.Google Scholar
  23. 23.
    Kang UG, Schecter H. (1978) J. Amer. Chem. Soc., 100, 651–652.CrossRefGoogle Scholar
  24. 24.
    Bru N, Vilarrasa J. (1980) Chemistry Letters, 1489–1492.Google Scholar
  25. 25.
    Rofstad EK, Brustad T, Johannessen JV, Mossige J. (1977) Br. J. Radial., 50, 314–320.CrossRefGoogle Scholar
  26. 26.
    Rauth AM, Mohindra JK.(1981) Cancer Res., 41, 4900–4905.PubMedGoogle Scholar
  27. 27.
    Stevens MFG, Simmonds RJ, Langdon SP. Unpublished results.Google Scholar
  28. 28.
    Pool BL. (1979) J. Cancer Res. Clin. OncoZ., 93, 221–231.CrossRefGoogle Scholar
  29. 29.
    Hansch C, Smith N, Engle R, Wood H. (1972) Cancer Chemother. Reports, 56, 443–456.Google Scholar
  30. 30.
    Hatheway GJ, Hansch C, Kim KH, Milstein SR, Schmidt CL, Smith RN, Quinn FR. (1978) J. Medicin. Chem., 21, 563–574.CrossRefGoogle Scholar
  31. 31.
    Edwards SL, Sherfinski JS, Marsh RE. (1974) J. Amer. Chem. Soc., 96, 2593–2597.CrossRefGoogle Scholar
  32. 32.
    Kolar GF, Preussmann R. (1971) Z. Naturforsch. B, 26, 950–953.PubMedGoogle Scholar
  33. 33.
    Dunn WJ, Greenberg MJ, Callejas SS. (1976) J. Medicin.Chem. 19, 1299–1301.CrossRefGoogle Scholar
  34. 34.
    Giraldi T, Guarino AM, Nisi C, Sava G. (1980) Pharmacol. Res. Commun., 12, 1–11.PubMedCrossRefGoogle Scholar
  35. 35.
    Sava G, Giraldi T, Lassiani L, Nisi C. (1979) Cancer Treatment Reports, 63, 93–98.PubMedGoogle Scholar
  36. 36.
    Connors TA, Goddard PM, Merai K, Ross WCJ, Wilman DEV. (1976) Biochem. Pharmacol., 25, 241–246.PubMedCrossRefGoogle Scholar
  37. 37.
    Audette RCS, Connors TA, Mandel HG, Merai K, Ross WCJ. (1973) Biochem. Pharmacol., 22, 1855–1864.PubMedCrossRefGoogle Scholar
  38. 38.
    Puccetti P, Giampietri A, Fioretti MC. (1978) Experientia, 15, 799–800.CrossRefGoogle Scholar
  39. 39.
    Haffner F, Christoffersen T. (1980) Acta Pharmacol. EtToxicol., 47, 93–97.CrossRefGoogle Scholar
  40. 40.
    Preussmann R, von Hodenberg A, Hengy H. (1969) Biochem. Pharmacol., 18, 1–13.PubMedCrossRefGoogle Scholar
  41. 41.
    Mizuno NS, Decker RW, Zakis B. (1975) Biochem. Pharmacol., 24, 615–619.PubMedCrossRefGoogle Scholar
  42. 42.
    Skibba JL, Ramirez G, Beal DD, Bryan GT. (1970) Biochem. Pharmacol., 19, 2043–2051.PubMedCrossRefGoogle Scholar
  43. 43.
    Hickman JA. (1978) Biochimie, 60, 997–1002.CrossRefGoogle Scholar
  44. 44.
    Hansch C, Hatheway CJ, Quinn FR, Greenberg N. (1978) J. Medicin. Chem., 21, 574–577.CrossRefGoogle Scholar
  45. 45.
    Giraldi T, Nisi C, Sava G. (1975) Biochem. Pharmacol., 24, 1793–1797.PubMedCrossRefGoogle Scholar
  46. 46.
    Pittillo RF, Schabel FM, Skipper HE. (1970) Cancer Chemother. Reports, 54, 137–142.Google Scholar
  47. 47.
    Gescher A, Hickman JA, Simmonds RJ, Stevens MFG, Vaughan K. (1981) Biochem. Pharmacol., 30, 89–93.PubMedCrossRefGoogle Scholar
  48. 48.
    Farina P, Gescher A, Hickman JA, Horton JK, D’Incalci M, Ross D, Stevens MFG, Torti L. Biochem. PharmacoZ., in press.Google Scholar
  49. 49.
    Gescher A, Hickman JA, Simmonds RJ, Stevens MFG, Vaughan K. (1978) Tetrahedron Letters, 5041–5044.Google Scholar
  50. 50.
    Julliard M, Vernin G, Metzger J. (1980) Synthesis, 116–117.Google Scholar
  51. 51.
    Horton JK, Stevens MFG. Unpublished results.Google Scholar
  52. 52.
    H. Zollinger. (1961) Diazo and Azo Chemistry. Interscience New York, p.185.Google Scholar
  53. 53.
    Hickman JA, Simmonds RJ, Kolar GF, (1980) Brit. J. Cancer, 142, 170.Google Scholar
  54. 54.
    Hickman JA. Unpublished results.Google Scholar
  55. 55.
    Kolar GF, Carubelli R. (1979) Cancer Letters, 7, 209–214.PubMedCrossRefGoogle Scholar
  56. 56.
    Kolar GF, Maurer M, Wildschütte. (1980) Cancer Letters, 10, 235–241.PubMedCrossRefGoogle Scholar
  57. 57.
    Ti Li Loo, Luce JK, Jardine JH, Frei E. (1968) Cancer Res., 28, 2448–2453.PubMedGoogle Scholar
  58. 58.
    Stevens MFG, Gescher A, Turnbull CP. (1979) Biochem Pharmacol., 28, 769–776.PubMedCrossRefGoogle Scholar
  59. 59.
    Schwalbe CH, Simmonds RJ. Unpublished work.Google Scholar
  60. 60.
    Akhtar MH, McDaniel RS, Feser M, Oehlschlager AC. (1968) Tetrahedron, 24, 3899–3906.CrossRefGoogle Scholar
  61. 61.
    Hopfinger AJ, Potenzone R. (1982) Mol. PharmacoZ., 21, 187–195.Google Scholar
  62. 62.
    Gescher A, Hickman JA, Stevens MFG. (1979) Biochem. Pharmacol., 28, 3235–3238.PubMedCrossRefGoogle Scholar
  63. 63.
    Lassiani L, Nisi C, Sigon F, Sava G, Giraldi T. (1980) J. Pharm. Sci., 69, 1098–1099.PubMedCrossRefGoogle Scholar
  64. 64.
    Clarke DA, Phillips FS, Sternberg SS, Barclay RK, Stock CC. (1953) Proc. Soc. Exp. Biol. Med., 84, 203–207.PubMedGoogle Scholar
  65. 65.
    Horton JK, Farina P, Gescher A, Hickman JA, Stevens MFG. Br. J. Cancer, in press.Google Scholar
  66. 66.
    Weinkam RJ, Shiba DA. (1978) Life Sciences, 22, 937–946.PubMedCrossRefGoogle Scholar
  67. 67.
    Ionescu D, Neagu V, Dobre V, Niculescu-Duvaz I. (1981) Neoplasma, 28, 19–26.PubMedGoogle Scholar
  68. 68.
    Noyanalpan N, Özden S, Özden T. (1977) Ankara Ecz. Fak. Mec., 7, 104–110.Google Scholar
  69. 69.
    Giraldi T, Nisi C, Connors TA, Goddard PM. (1977) J. Medicin. Chem., 20, 850–853.CrossRefGoogle Scholar
  70. 70.
    Dunn WJ, Greenberg MJ. (1977) J. Pharm. Sci., 66, 1416–1419.PubMedCrossRefGoogle Scholar
  71. 71.
    Giraldi T, Goddard PM, Nisi C, Sigon F. (1980) J. Pharm. Sci., 69, 97–98.PubMedCrossRefGoogle Scholar
  72. 72.
    Cowan DH, Bergsagel DE. (1971) Cancer Chemother. Reports, 55, 175–181.Google Scholar
  73. 73.
    Tronchet JMJ, Rachidzadeh F. (1979) Hely. Chini. Acta, 62, 971–977.CrossRefGoogle Scholar
  74. 74.
    Larm O, Larsson K, Wannong M. (1977) Acta Chem. Scand., B31, 475–478.CrossRefGoogle Scholar
  75. 75.
    Baki Av, Vaughan K. Carbohydrate Res., in press.Google Scholar
  76. 76.
    Baker BR. (1967) Design of Active-Site-Directed Irreversible Enzyme Inhibitors. John Wiley and Sons, Inc., New York.Google Scholar
  77. 77.
    Sinnott ML, Smith PJ. (1976) J.C.S. Chem. Commun., 223–224.Google Scholar
  78. 78.
    Godin JRP, Llanos G, Vaughan K, Renton KW. (1981) Can. J. Physiol. Pharmacol., 59, 1239–1244.PubMedCrossRefGoogle Scholar
  79. 79.
    Stevens MFG. Unpublished results.Google Scholar
  80. 80.
    Comis RL. (1976) Cancer Treatment Reports. 60, 165–176.PubMedGoogle Scholar
  81. 81.
    Lin AJ, Ti Li Loo. (1978) J. Medicin. Chem., 21, 268–272.CrossRefGoogle Scholar
  82. 82.
    Wilman DEV, Goddard PM. (1980) J. Medicin. Chem., 23, 1052–1054.CrossRefGoogle Scholar
  83. 83.
    Wilman DEV. Personal communication.Google Scholar
  84. 84.
    O’Connor JE, Janusonis GA, Corey ER. (1968) Chem. Commun., 445–446.Google Scholar
  85. 85.
    Kuyper J, Van Vliet PI, Vrieze K. (1975) J. OrganometaZlic Chem., 96, 289–299.CrossRefGoogle Scholar
  86. 86.
    Pfeiffer E, Kuyper J, Vrieze K. (1976) J. Organometallic Chem., 105, 371–378.CrossRefGoogle Scholar
  87. 87.
    Kuyper J, Van Vliet PI, Vrieze K. (1976) J. Organometallic Chem., 105, 379–387.CrossRefGoogle Scholar
  88. 88.
    Van Vliet PI, Kuyper J, Vrieze K. (1976) J. Organometallic Chem., 122, 99–111.CrossRefGoogle Scholar
  89. 89.
    Iwata H, Yamamoto I, Muraki K. (1969) Biochem. Pharmacol., 18, 955–956.PubMedCrossRefGoogle Scholar
  90. 90.
    Iwata H, Yamamoto, Gohda E, Morita K, Nishino K. (1972) Biochem. Pharmacol., 21, 2141–2144.PubMedCrossRefGoogle Scholar
  91. 91.
    Iwata H, Yamamoto I, Gohda E. (1973) Biochem. PharmacoZ., 22, 1845–1854.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, The Hague, Boston, London 1983

Authors and Affiliations

  • M. F. G. Stevens

There are no affiliations available

Personalised recommendations